Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies
Catherine Thiéblemont(Université Paris Cité), Paolo Ghia(Vita-Salute San Raffaele University), Neil E. Kay(Mayo Clinic), Vanessa Innao, Mark Wildgust(Bristol-Myers Squibb (United States)), Galia Stemer(Western Galilee Hospital), Ingo Schwaner(Praxis für Hämatologie und Onkologie), Tamar Tadmor(Bnai Zion Medical Center), Claire Kavanagh(Johnson & Johnson (Ireland)), Christoph Tapprich(Johnson & Johnson (Germany)), Talha Munir(St James's University Hospital), Adriana Scheliga(Instituto de Oncologia do Paraná), Ugo Consoli(Ospedale Garibaldi), Oliver Miles(Musgrove Park Hospital), Emmanuelle Tchernonog(Centre Hospitalier Universitaire de Montpellier), Danielle De Farias(Beneficência Portuguesa de São Paulo), Anna Mele, Ahmed Absi(National Guard Health Affairs), Sowmya Srikanthan(Johnson & Johnson (United States)), Ping Xu(Beijing Proteome Research Center), Mohamed Fouad(Johnson & Johnson (United States)), Mark A. Hoffman(University of San Diego), Erin Franceschini(AbbVie (United States)), Lori Parisi(Janssen (United States)), Boo Messahel(Royal Marsden NHS Foundation Trust), Brian Koffman(Precision Research Institute)
Cited by 0
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890